personalized medicine
Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance
Intermountain will use Tempus' next-generation sequencing-based cancer assay to study patient samples to advance research into precision patient care.
Avalon GloboCare, Lu Daopei Hematology Institute Partner to Develop Cell Therapy CDx
The deal, which is subject to negotiation, will help Avalon create diagnostics for personalizing its current and future cell immunotherapy programs.
Oncocyte Q1 Revenues Rise 27 Percent on DetermaRx Activity
The Irvine, California-based diagnostics firm reported $1.4 million in revenue, missing the consensus Wall Street estimate of $2.2 million.
The firm is hoping that growing real-world evidence for DecisionDx-Melanoma will support better clinical recognition as it continues to expand its menu.
Guidelines Update Supports Use of Genomic Tests in Early Prostate Cancer Management
Although authors cautioned against routine testing, they wrote that clinicians may consider genomic testing in cases where it might change their clinical decisions.